Exporting THC from Jamaica to US Now Legal

Pure Jamaican and its GMP-certified, licensed pharma manufacturer Seven-10 Pharmaceuticals are now legally exporting proprietary pharmaceutical products with cannabis-derived THC, as well as hemp-derived CBD and other cannabinoids, to the US, Brazil and other major international markets.

The permissions to export Pure Jamaican pharmaceutical products containing THC to the US were granted by Jamaica's Ministry of Health & Wellness (MOHW) to Seven-10 Pharmaceuticals pursuant to valid corresponding import permits received from the US Drug Enforcement Administration (DEA). The products were shipped to a DEA-licensed facility in the US for successful analytical testing.

Once the DEA approves the rescheduling of THC from Schedule 1 to Schedule 3 under the Controlled Substances Act, as is anticipated, Seven-10 intends to request DEA permits to ship Pure Jamaican pharmaceutical THC products from Jamaica to patients in the US, subject to valid doctor prescriptions and all relevant DEA, FDA and state pharmacy distribution regulations.

In the Controlled Substances Act, Schedule 1 means it is deemed to have a high likelihood of abuse and no medical uses. The Department of Health and Human Services is recommending that the DEA significantly loosen federal restrictions on marijuana, which is considered Schedule 3. This change, said Politico, is potentially the biggest change in federal drug policy in decades.

Meanwhile, Seven-10 has already begun shipping Pure Jamaican's Botanicos pharmaceutical tinctures with THC and other cannabinoids directly to patients in Brazil, pursuant to ANVISA import permits. Together, Brazil and the US represent populations of more than 500 million people, providing tremendous potential demand.

"This is a proud moment for Jamaica, and for our group of companies. ... As the only company in Jamaica licensed for pharmaceutical manufacturing of cannabinoids, we are proud to be leading the way to elevating the role of Jamaica in the global cannabis ecosystem," said Scott Cathcart, CEO of Pure Jamaican and Seven-10 Pharmaceuticals.